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It has become increasingly clear that receptor tyrosine kinases (RTKs) are playing a 
major role in cancer development. They form a sub-class of cell-surface growth factor 
receptors with intrinsic ligand controlled tyrosine kinase activity. RTKs regulate 
crucial biological processes in the cell, but when mutated, they can become 
constitutively activated or display altered signalling properties, i.e. they become 
oncoproteins. Understanding the molecular bases of cancer will not only help us to get 
better insights in genotype-phenotype correlations, it might also help in designing new 
therapeutic approaches. Indeed, RTK-based therapies have reached widespread 
clinical use in, for instance, breast cancer (inhibition of HER2 by Herceptin), 
gastrointestinal stromal tumours (inhibition of KIT by Glivec) and non-small cell lung 
cancer (inhibition of EGFR by Gefitinib) (1).  
In this thesis we describe one such cancer-related RTK, namely RET, and the 
signalling pathways in which is involved. Molecular and genetic aspects have been 
reviewed in the Introduction. In this Discussion we review current knowledge of 
mutant RET signalling, our own contribution to topic and how RET may be 
considered and used as a therapeutic target in MEN2.  
  
MUTANT RET SIGNALLING 
Gain of function mutations of RET result in constitutive activation of the receptor and 
cause MEN2. Our understanding of the molecular mechanisms that connect the 
mutant receptors to the different clinical MEN2 subtypes is increasing.    
The specific temporal adjustment of ligand-induced AKT activation appears to be 
dependent of co-localization of RET in lipid rafts and this control step is bypassed by 
mutant RETC634R associated with MEN2A, indicated as RET-MEN2A (2). Other 
studies suggest that mutant RET causing MEN2B, indicated as RET-MEN2B, results 
in a different pattern of receptor (tyrosine) phosphorylation and in altered substrate 
specificity (3). Liu and colleagues (3) found that compared to wild type RET (RET-
WT), the RET-MEN2B mutant lacked phosphorylation at Tyr 1096, directly leading 
to decreased GRB2 binding. Furthermore, expression of MEN2B mutant RET-PTC2 
results, in contrast to the activated wild type receptor, in tyrosine phosphorylation of a 
number of proteins that interact with CRK and NCK (4). Among them is one of the 
CRK associated proteins, namely PAXILLIN, a cytoskeleton protein. PAXILLIN is 
strongly phosphorylated in RET-MEN2B, but not in RET-WT-expressing cells (4). 
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Furthermore, RET-MEN2B-expressing cells show selective activation of JNK-1 (5). 
These studies demonstrate that differences in signalling properties exist between 
RET-WT on one hand and RET-MEN2A and RET-MEN2B on the other.           
Studies comparing RET-MEN2A with either RET-MEN2B or RET-FMTC have been 
conducted as well. Tyrosine 1096, which is only found in the long isoform of the 
receptor, is phosphorylated in RET-MEN2A, but not in RET-MEN2B oncoproteins 
(3). Moreover, the MEN2B and FMTC-associated intracellular mutants have altered 
substrate specificity as in contrast to the normal substrates of receptor tyrosine 
kinases, they recognize and phosphorylate substrates preferred by cytoplasmic 
tyrosine kinases, such as c-SRC and c-ABL (5, 6). Additionally, RET-MEN2B 
oncoproteins trigger higher levels of activated PI3K and its downstream signalling 
molecules. For instance, P62DOK and PKB/AKT are phosphorylated in a PI3-K 
dependent manner and their levels of phosphorylation are significantly higher in 
MEN2B than in MEN2A cell lines (7). Moreover, tyrosine phosphorylation of 
P62DOK results in complex formation with the RAS GTPase-activating protein 
(RAS-GAP) and the NCK adaptor protein. These findings suggest that high levels of 
activation of PI3-K and its downstream signalling molecules may be associated with 
the clinical phenotype of MEN2B (7). In the same line of evidence, phosphorylation 
of RET tyrosine 1062 is stronger in RET-MEN2B than in RET-MEN2A (8). 
Phosphorylated tyrosine 1062 is part of a RET multiple effector docking site that 
mediates recruitment of the SHC adapter. RET-MEN2B is more active than RET-
MEN2A in associating with SHC and hence the MEN2B mutant specifically 
potentates the ability of RET to auto-phosphorylate tyrosine 1062 and consequently 
triggers higher activation levels of the RAS/MAPK and the PI3-K/AKT pathways, 
respectively. The more efficient triggering of these pathways likely contributes to the 
difference between the MEN2A and MEN2B phenotypes (8).  
STATs are a family of latent transcription factors involved in the activation of many 
genes induced by cytokines and growth factors (9). STATs when aberrantly activated, 
contribute to cancer development (9).  In particular STAT3 has been shown to be 
aberrantly activated in many types of cancers, such as myelomas, leukaemia, 
lymphomas, melanoma, prostate, ovary, head and neck carcinomas and MTCs (10). 
Oncogenic transactivation of STAT3 by RET-MEN2A C634R is required for cellular 
transformation, and this process is mediated by the intrinsic tyrosine kinase domains 
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of RET, independently of JAKs and SRC (11). In contrast, the FMTC-associated 
mutants RETY791F and RETS891A implicate SRC and JAKs in constitutive 
activation of STAT3 (10). These results suggest that RET mutants, associated with 
different disease phenotypes, activate STAT3 through different signalling routes. It is 
still not completely understood how SRC and JAKs interact with the different RET 
mutants in order to promote aberrant activation of STAT3. In the same line, Yuang 
and colleagues demonstrated that RET-MEN2B was able to interact and activate 
STAT3 with more affinity than RET-MEN2A mutants (12). These results corroborate 
a previous finding (6, 13) in which RET-MEN2B mutants were shown to be 
specifically associated with SRC for which STAT3 is one of the most well 
characterised targets.  
All this points towards specific signalling profiles triggered by RET mutants 
associated with specific MEN2-disease phenotypes. In Chapter 4 we have compared 
ERK1/2 and STAT3 activation by specific MEN2-RET oncoproteins. The activation 
levels of both pathways correlated strongly with the degree of phosphorylation of 
RET Tyr1062 and RET Tyr981, respectively. Moreover, levels of RET Tyr1062 and 
Tyr918 were up-regulated by co-expression of a constitutive active SRC (v-SRC). 
The fact that RET S891A, RETA883F and RETM918T were most affected suggests 
in trans phosphorylation of RET by v-SRC as a possible oncogenic mechanism of 
receptor activation for point mutations in the proximity of or within the P+1 loop of 
the catalytic domain of RET.  
 
In this thesis we focussed on three main pathways. Our results are discussed in more 
detailed below.  
 
Specific ERK1/2 signalling by distinct MEN 2-associated RET mutants 
MAPK kinase (ERK1/2) signalling plays a crucial role in the regulation of cell growth 
and differentiation (14). Upon growth factor stimulation, adaptor proteins will connect 
the receptor with guanidine exchange factors and activate RAS, which in turn will 
initiate a protein kinase cascade involving RAF, MEK1/2, ERK1/2 and ending with 
the regulation of ELK-1 and P90RSK transcription factors (14).   
Deregulation of these pathways by oncogenes, such as RET, is one of the hallmarks of 
cancer development (15). RET-MEN2 activates the RAS/ERK1/2 pathway 
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independent of GDNF (see for instance Chapter 3, Figure 2A). We could demonstrate 
differences in the degree of ERK1/2 phosphorylation, by the different RET mutations 
associated with the MEN2-disease phenotypes (see Chapter 4, Figure 1). We showed 
that RET-MEN2B M918T induced higher levels of ERK1/2 phosphorylation than 
with RET-MEN2A C634R and (in decreasing order) RET-MEN2B A883F, RET-
FMTC S891A, RET-FMTC Y791F and RET-MEN2A C620R, respectively. These 
finding strongly correlate with the levels of RET tyrosine 1062 phosphorylation 
displayed by the different RET mutants (Figure 1, Chapter 4), with the exception of 
RET-FMTC S891A. This suggests that RETS891A could preferentially trigger others 
signalling pathways than the RAS/ERK1/2 route via tyrosine 1062. Taken together all 
these results suggest that a differential degree of the ERK1/2 activation by mutant 
RET contributes to the clinical differences observed in MEN2. 
 
STAT3 activation by distinct MEN2-associated RET mutants 
STAT3 activation by cytokine receptors (which lack intracellular kinase domains) 
involves members of the JAK family of kinases (9), whereas STAT3 activation by 
tyrosine kinases receptors seems to be mediated by the kinase domain of the receptor 
itself. However, this mechanism is not completely understood. In the case of RET (as 
shown in Chapter 2), constitutive activation of STAT3 by two FMTC mutations 
(RETY791F and RETS891A) was SRC and JAK1/2 dependent. For the RET-MEN2A 
mutation RETC634R constitutive activation of STAT3 is independent of JAKs and 
SRC (11). These results suggest that different mutant RET receptors can activate 
STAT3 via different mechanisms. 
STAT3 activation is triggered by tyrosine 705 phosphorylation, which results in 
dimerization and nuclear translocation (9). Activation of STAT3 can be further 
enhanced by phosphorylation of Ser727, located in the TAD domain (c-terminal 
transcriptional activator domain).  In Chapter 3, we showed that RET was able to 
induce STAT3 Ser727 phosphorylation via a RAS/RAF/MEK1-2/ERK1-2 pathway. 
Interestingly, integration of the ERK1/2 and STAT3 pathways was only achieved by 
oncogenic RET (RETC634R, Y791F and S891A). Wild type RET did not induce 
STAT3 Tyr705 phosphorylation. Thus, interplay between the STAT3 and ERK1/2 
pathways by oncogenic RET may play an important role in the development of 
MEN2. 
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Phosphorylation of RET in trans by SRC  
SRC and the SRC-tyrosine kinase family of proteins are regulatory proteins that play 
key roles in cell differentiation, motility, proliferation and survival (16). The SRC-
kinase family of proteins is highly regulated and interacts with a wide variety of 
molecules, such as growth factor receptors, integrin receptors, G-protein couple 
receptors, cytokine receptors and steroid hormone receptors (16). Several molecules 
have been shown to be downstream substrates of SRC, such as P85 (the regulatory 
subunit of PI3-K), RAS-GAP, SHC, PLC-γ, several integrin signalling proteins and 
FAK (16). Interestingly, all these molecules have also been shown to be downstream 
substrates of the RET receptor (6, 17). Furthermore, during signalling an interaction 
between SRC and wild type RET via Tyr981 was demonstrated (18) albeit under the 
specific condition of an overexpression of both wild type RET and SRC in HEK293 
cells (18). In another study by Kato et al. (19), a novel SRC kinase-mediated repair 
mechanism of function-impaired RET mutants is reported. 
In Chapter 4, we showed that the RET-MEN2B mutants (RETA883F and RET 
M918T) and the RET-FMTC mutant (RET S891A) affecting the intracellular part of 
the RET protein display higher levels of phosphorylation of tyrosine 981 (the SRC 
docking site) and tyrosine 1062 phosphorylation, than other MEN2-FMTC mutants. 
The level of tyrosine 981 phosphorylation seems to correlate with the position of the 
disease-associated mutations, in the sense that the highest levels of phosphorylation 
are found associated with mutations close to or within the P+1 loop motif.  
The levels of tyrosine 981 phosphorylation (and hence SRC activation) strongly 
correlate with the levels of STAT3 Tyr705 phosphorylation. This finding is 
strengthened by the fact that STAT3 is one of the main and best-characterized SRC 
target molecules (13). The strong interaction between RET and SRC was further 
confirmed by transfecting either wild type RET or specific RET mutants in 
combination with a constitutively active SRC in HEK293 cells (see Figure 1, Chapter 
4). In these experiments, phosphorylation levels of RET Tyr1062 and Tyr918 were 
up-regulated and interestingly, RET mutants RETS891A, RETA883F and 
RETM918T were most affected by SRC. Taken all together, these results suggest that 
phosphorylation in trans of RET by SRC is a novel mechanism of oncogenic RET 
activation, in particularly for those intracellular mutants targeting the P+1 loop of the 
kinase domain. 
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In summary, evidence is accumulating signalling profiles exist that are RET mutation-
specific. It should be noted, that most of these studies, including ours, have been 
performed in artificial systems using: 
i) cells derived from medullary thyroid carcinomas or ii)  transient and established cell 
lines not always relevant to the pathobiology of RET. This and the fact that mostly 
specific substrates/pathways have been examined makes it likely that the present 
delineation of these RET mutation specific signaling profiles which underlie the 
different MEN2 clinical phenotypes, is far from complete. 
 
RET AS A THERAPEUTIC TARGET 
The successful inhibition of a variety of tyrosine kinases has been a recent success in 
the fight against cancer.  Examples are Herceptin, Glivec and Gefitinib in breast 
cancer, gastrointestinal stromal tumours and non-small cell lung cancers, respectively 
(1). These findings have directed attention to RET as a possible therapeutic target in 
particular in MEN2 and FMTC (20) as no systematic treatment is yet available. All 
the crucial steps in the activation and signalling of RET, including dimerization, 
autophosphorylation, recruitment of adaptor proteins to various docking sites and 
initiation of signal-transduction cascades may be targets of specific inhibitors. 
  
Drugs interfering with the dimerization of RET  
The neutralizing, nuclease-resistant D4 aptamer is capable of binding and inhibiting 
wild type RET and RET-MEN2A mutant on the cell surface. The fact that monomeric 
RET-MEN2B was not affected suggests that D4 acts by interfering with the formation 
of a stable, active RET dimmers (21). The efficacy of D4 application as a therapeutic 
tool for RET-associated tumours needs, however, to be established. 
 
Drugs interfering with the autophosphorylation of RET  
Several RET tyrosine kinase inhibitors have been identified over the last years. 
Imatinib, a 2-phenylaminopyrimidine, has been shown to display inhibitory activity 
against RET-MEN2A and RET-MEN2B in MTC-derived cell lines and to induce 
RET degradation. Concentrations resulting in growth inhibition were, however, 
relatively high. Consequently, Imatinib will most likely not be a good candidate for 
systemic therapy in RET-associated tumours (22, 23). However, encouraging results 
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were obtained using other tyrosine kinase inhibitors such us CEP-701 and CEP-751 
(20). Therefore, tyrosine kinase inhibitors might become a suitable therapy for RET-
associated cancers, although as this has already been demonstrated for RET (24), the 
development of resistance may pose a problem in tumours treated by these agents.  
 
Drugs interfering with the recruitment of adaptor proteins 
It has been shown that SHP-1, a cytoplasmic phosphatase, can associate with mutant 
RET, reducing its autophosphorylation rate and consequently suppressing the growth-
promoting signals of the RET-induced MAPK pathway (25, 26). This reduction in 
autophosphorylation is activated by somatotropin release-inhibiting factor (SRIF) 




Proteins downstream of RET in different signalling pathways might be inhibited 
resulting in a modulation of the effects caused by the (mutant) protein. Several 
inhibitors that target the RAS/RAF/MEK/ERK pathway- a signalling route activated 
by RET (see Chapter 3), are under clinical evaluation in non-RET-associated human 
cancer (27). Of particular interest in RET-associated tumours is the bi-aryl urea BAY 
43-9006 (sorafenib), which was initially developed as a specific inhibitor of BRAF. 
However, subsequent studies revealed that BAY 43-9006 also inhibits other kinases 
including RET (Plaza-Menacho and Hofstra, unpublished data). The simultaneous 
action at two levels of the same signalling pathway (RET and BRAF) in endocrine 
tumours may offer a perspective to avoid the development of treatment resistance. 
Internalization and nuclear translocation  
Targeting RET with a monoclonal antibody may be a useful therapeutic approach for 
neural crest cell derived cancers. Yano et al. have generated an antibody capable of 
causing internalization of RET, but its efficacy has not yet been demonstrated (28). 
 
Biosynthesis  
Gene therapeutic approaches involving the integration of new genetic material into the 
genome can be used to replace defective genes or to alleviate the effects of unwanted 
  Chapter 7 
 128
ones by the introduction of a counteracting gene. Inhibition of oncogenic RET 
signalling by expression of a dominant-negative RET mutant has been investigated 
and reviewed by Putzer et al (20). Another gene therapeutic approach may be the 
introduction of a RET-selective ribozyme that specifically cuts mutant RET RNA and 
blocks RET-mediated cell growth and transformation (29). 
 
In conclusion, the RET receptor represents a potential target for the neuroendocrine 
tumours observed in MEN2 in which RET dysfunction plays a crucial role. 
Elucidation of the signalling properties of specific RET mutants associated with the 
three clinical subtypes will help to uncover the molecular basis of the MEN2 disorder 
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